Source 1review2024MED
Toolkit/blood-brain barrier opening
blood-brain barrier opening
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
We highlight the following technologies: ... blood-brain barrier opening...
Usefulness & Problems
No literature-backed usefulness or problem-fit explainer has been materialized for this record yet.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Mechanisms
blood-brain barrier openingmicrobubble-assisted blood-brain barrier openingultrasound-mediated permeability modulationTechniques
Computational DesignTarget processes
No target processes tagged yet.
Input: Light
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
The reviewed studies establish the basis for novel and promising neuromodulatory treatments for Parkinson disease motor symptoms.
These studies establish the basis for novel and promising neuromodulatory treatments for PD motor symptoms.
The review summarizes preclinical and clinical trials investigating innovative neuromodulatory approaches for Parkinson disease motor symptom management.
In this review, we summarize preclinical and clinical trials investigating innovative neuromodulatory approaches for Parkinson disease (PD) motor symptom management.
The review highlights temporal interference, nanoparticles for drug delivery, blood-brain barrier opening, gene therapy, optogenetics, upconversion nanoparticles, magnetothermal nanoparticles, magnetoelectric nanoparticles, ultrasound-responsive nanoparticles, and DREADDs as relevant technologies for Parkinson disease.
We highlight the following technologies: temporal interference, nanoparticles for drug delivery, blood-brain barrier opening, gene therapy, optogenetics, upconversion nanoparticles, magnetothermal nanoparticles, magnetoelectric nanoparticles, ultrasound-responsive nanoparticles, and designer receptors exclusively activated by designer drugs.
Approval Evidence
1 source3 linked approval claimsfirst-pass slug blood-brain-barrier-opening
We highlight the following technologies: ... blood-brain barrier opening...
Source:
promise assessmentsupports
The reviewed studies establish the basis for novel and promising neuromodulatory treatments for Parkinson disease motor symptoms.
These studies establish the basis for novel and promising neuromodulatory treatments for PD motor symptoms.
Source:
review scope summarysupports
The review summarizes preclinical and clinical trials investigating innovative neuromodulatory approaches for Parkinson disease motor symptom management.
In this review, we summarize preclinical and clinical trials investigating innovative neuromodulatory approaches for Parkinson disease (PD) motor symptom management.
Source:
technology scopesupports
The review highlights temporal interference, nanoparticles for drug delivery, blood-brain barrier opening, gene therapy, optogenetics, upconversion nanoparticles, magnetothermal nanoparticles, magnetoelectric nanoparticles, ultrasound-responsive nanoparticles, and DREADDs as relevant technologies for Parkinson disease.
We highlight the following technologies: temporal interference, nanoparticles for drug delivery, blood-brain barrier opening, gene therapy, optogenetics, upconversion nanoparticles, magnetothermal nanoparticles, magnetoelectric nanoparticles, ultrasound-responsive nanoparticles, and designer receptors exclusively activated by designer drugs.
Source:
Comparisons
No literature-backed comparison notes have been materialized for this record yet.
Ranked Citations
- 1.